Max Planck Institute of Biochemistry

FamilyTreeDNA and University of Cambridge Lead Research Study that Reveals the Most Famous Beethoven Wasn't Genetically a Beethoven

Retrieved on: 
목요일, 3월 23, 2023
Family Tree DNA, Max Planck Institute of Biochemistry, Nobel Prize, DNA, Hair, Male, Arrest, Life, Haplogroup R1b, EPP, GGT, University of Cambridge, Research, Alcoholism, DNA repair, Torture, Hearing, Witchcraft, Fraud, Trauma, News, Max Planck Society, Genome, Forestry, Microscope, Vaccine

HOUSTON, March 23, 2023 /PRNewswire-PRWeb/ -- Ludwig van Beethoven's genome was recently sequenced by an international team of scientists and it revealed some shocking information about his family history.

Key Points: 
  • Now, researchers have used DNA to show that Ludwig, the most famous Beethoven, is not genetically related to other living Beethovens.
  • Back in 2020, researchers at Cambridge University and the Max Planck Institute sequenced the DNA from several locks of hair attributed to Ludwig.
  • The research team contacted living descendants of Aert van Beethoven (1535–1609), Ludwig's supposed 5th great-grandfather.
  • The five present-day descendants of Aert van Beethoven belong to haplogroup R1b, whereas Ludwig van Beethoven belongs to haplogroup I1.

Sensei Biotherapeutics Provides Update on Strategic Priorities

Retrieved on: 
목요일, 12월 8, 2022
Max Planck Institute of Biochemistry, CD39, Investigational New Drug, Concluding observations on the second periodic report of the Holy See, Ludwig Maximilian University of Munich, Neoplasm, Max Planck Society, Tumor microenvironment, Amgen, Biochemistry, Chemistry, Daiichi Sankyo, Max Planck Institute of Neurobiology, FDA, Safety, Cancer, VISTA, Doctor of Philosophy, Schmidt Science Fellows, Workforce, Research, IND, Risk, OncoMed, ...Continued, Patient, Therapy, Vaccine, Pharmaceutical industry, Management, Sensei

BOSTON, Dec. 08, 2022 (GLOBE NEWSWIRE) -- eSensei Biotherapeutics, Inc. (Nasdaq: SNSE), an immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients, today announced a streamlining and realignment of resources to support its key indications and programs, including its lead antibody, SNS-101, a conditionally active antibody targeting the immune checkpoint VISTA, as well as its other TMAb™ (Tumor Microenvironment Activated biologics) platform programs.

Key Points: 
  • Sensei plans to relocate any ongoing work at its Boston research site to its Rockville, Maryland site.
  • “Our Board of Directors and management team remain focused on ensuring that Sensei is well positioned to execute on our near-term clinical and preclinical milestones.
  • Prior to joining Sensei in 2019, Dr. van der Horst worked at Zenith Epigenetics Ltd., Igenica Biotherapeutics Inc., OncoMed Pharmaceuticals, Tularik, Inc. (now Amgen) and U3 Pharma GmbH (now Daiichi-Sankyo).
  • Sensei Biotherapeutics (Nasdaq: SNSE) is an immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients.

EQS-News: Proteros and Adrestia initiate multi-target partnership to discover first-in-class drugs for intractable genetic diseases

Retrieved on: 
금요일, 10월 28, 2022
Diamond, Drug discovery, Max Planck Society, Drug development, Villigen, Disease, Gesellschaft mit beschränkter Haftung, Drug design, Probability, GSK, Olaparib, Lists of diseases, Max Planck Institute of Biochemistry, Joint Planning and Development Office, Biology, Science, University College London, Cancer, Gene, Nobel Prize, Genome, Partnership, Pharmaceutical industry, IND, Dodi Protero

Martinsried/Munich, Germany October 25, 2022 Proteros biostructures GmbH (Proteros) today announced that it has initiated a multi-target drug discovery partnership with Adrestia Therapeutics (Cambridge, UK), a leader in synthetic rescue therapies for genetic diseases.

Key Points: 
  • Martinsried/Munich, Germany October 25, 2022 Proteros biostructures GmbH (Proteros) today announced that it has initiated a multi-target drug discovery partnership with Adrestia Therapeutics (Cambridge, UK), a leader in synthetic rescue therapies for genetic diseases.
  • Proteros will provide access to its entire customizable platform of technologies for early drug discovery guided by the companys experienced discovery teams.
  • The partners will jointly discover lead compounds with the goal of further developing them into first-in-class drugs for intractable genetic diseases.
  • Adrestias carefully validated targets, discovered through their unique platform, and their broad potential in disease applications are an inspiration to Proteros.

Proteros and Adrestia initiate multi-target partnership to discover first-in-class drugs for intractable genetic diseases

Retrieved on: 
화요일, 10월 25, 2022
Diamond, Lists of diseases, Drug design, GSK, Disease, Science, Nobel Prize, Max Planck Institute of Biochemistry, Drug development, Biology, Villigen, Joint Planning and Development Office, Partnership, Olaparib, Max Planck Society, Probability, University College London, Drug discovery, Gesellschaft mit beschränkter Haftung, GLOBE, Genome, Gene, Cancer, Pharmaceutical industry, IND, Dodi Protero

Proteros will provide access to its entire customizable platform of technologies for early drug discovery guided by the companys experienced discovery teams.

Key Points: 
  • Proteros will provide access to its entire customizable platform of technologies for early drug discovery guided by the companys experienced discovery teams.
  • The partners will jointly discover lead compounds with the goal of further developing them into first-in-class drugs for intractable genetic diseases.
  • Adrestias carefully validated targets, discovered through their unique platform, and their broad potential in disease applications are an inspiration to Proteros.
  • We are delighted to support Adrestia in their accelerated drug discovery endeavors for a variety of complex targets to treat genetic diseases, said Dr. Debora Konz Makino, Proteros VP Business Unit Discovery Solutions.

Adrestia appoints Head of Chemistry and initiates multi-target partnership with Proteros to discover first-in-class drugs for intractable genetic diseases

Retrieved on: 
화요일, 10월 25, 2022
Health, General Health, Research, Pharmaceutical, Science, Biotechnology, Diamond, Lists of diseases, Master of Science, Drug design, Diamond Light Source, University of Nottingham, GSK, Therapy, Disease, Hope, Science, Amphisbaena, Nobel Prize, University, Max Planck Institute of Biochemistry, Drug development, Research, Joint Planning and Development Office, Villigen, Astex, Institute, Partnership, Olaparib, Artificial intelligence, Cancer, Gene, Max Planck Society, Probability, University College London, Drug discovery, Atlas, Doctor of Philosophy, Industry, Charles River Laboratories, Gesellschaft mit beschränkter Haftung, Cancer Research UK, Genetics, Genome, Head, GW Pharmaceuticals, Pharmaceutical industry, IND, Chemistry, Dodi Protero, Adrasteia

Im thrilled to be working with James and Proteros were poised to deliver some revolutionary new medicines.

Key Points: 
  • Im thrilled to be working with James and Proteros were poised to deliver some revolutionary new medicines.
  • He has led or been involved with the delivery of seven drug candidates across a range of target classes.
  • In Jamess most recent position he ran the medicinal chemistry function at Amphista Therapeutics.
  • Adrestia has developed a leading synthetic rescue drug development platform, which has already identified completely new targets for treating intractable genetic diseases.

Tevard Biosciences Appoints Zoya Ignatova to Its Scientific Advisory Board

Retrieved on: 
수요일, 8월 3, 2022
Whitehead Institute, Johns Hopkins School of Medicine, RNA Biology, Therapy, RNA, Max Planck Institute of Biochemistry, The German, Institute, Lists of diseases, Culture, Degenerative disease, American Society for Biochemistry and Molecular Biology, Department, UHH, Biotechnology, Father, Education, RNA transfection, MIT, Pathology, Genetics, Disease, Cell biology, Dravet syndrome, American Society for Cell Biology, Research, Muscular dystrophy, Bloomberg Distinguished Professorships, University of Potsdam, Bloomberg, Molecular biology, Biophysical Society, Silencer (firearm), University, Protein, SAB, University of Hamburg, Amplifier, Pharmaceutical industry, Medical device, Biochemistry, Enhancer

CAMBRIDGE, Mass., Aug. 3, 2022 /PRNewswire/ -- Tevard Biosciences, the pioneer of tRNA-based therapies for severe genetic diseases, today announced the appointment of leading tRNA scientist Zoya Ignatova, Ph.D, to its scientific advisory board.

Key Points: 
  • CAMBRIDGE, Mass., Aug. 3, 2022 /PRNewswire/ -- Tevard Biosciences , the pioneer of tRNA-based therapies for severe genetic diseases, today announced the appointment of leading tRNA scientist Zoya Ignatova, Ph.D, to its scientific advisory board.
  • "I'm fascinated by the many ways that tRNAs influence the vital process of making new proteins," said Dr. Ignatova.
  • Dr. Ignatova is a professor of RNA Biology and Managing director of the Institute of Biochemistry and Molecular Biology at the University of Hamburg (UHH), Germany.
  • Tevard Biosciences is pioneering mRNA-modulating therapies to cure a broad range of genetic diseases.

SCIEX Launches the Next Generation of Data Independent Acquisition With Zeno SWATH DIA at ASMS 2022

Retrieved on: 
월요일, 6월 6, 2022
Health, Technology, Nanotechnology, Other Technology, Research, Science, Biotechnology, Biomarker, Precision medicine, Research, Max Planck Institute of Biochemistry, Safety, Mass spectrometry, Francis Crick Institute, Disease, Solution, Health, SWATH, OMICS, Patient, Danaher Corporation, Technology, DHR, NYSE, Medicine, Drug development, Institute, Protein, Medical imaging, Silviculture, SCIEX

SCIEX , a global leader in life science analytical technologies, and a company of Danaher Corporation (NYSE:DHR), launches Zeno SWATH DIA, a significant step forward in biomarker discovery and translation workflows.

Key Points: 
  • SCIEX , a global leader in life science analytical technologies, and a company of Danaher Corporation (NYSE:DHR), launches Zeno SWATH DIA, a significant step forward in biomarker discovery and translation workflows.
  • This means the potential for the development of clinical tests for early detection of disease is vastly increased.
  • The sensitivity of Zeno SWATH DIA also enables large numbers of proteins to be quantified from sample loadings up to 10-fold lower than previous SWATH approaches.
  • With Zeno SWATH DIA we can now do studies that we couldnt do before due to cost alone.

ArriVent Biopharma Appoints Bahija Jallal to its Board of Directors

Retrieved on: 
화요일, 2월 15, 2022
Biochemistry, Patient, MedImmune, Receptor, Board, Max Planck Institute of Biochemistry, Molecular biology, Leadership, Board of directors, GLOBE, Therapy, AstraZeneca, Doctor of Philosophy, Arrival (company), Cancer, Johns Hopkins University, Max Planck Society, Growth, Research, Helmy Eltoukhy, University, Santaris Pharma, Trustee, Drug development, Management, Pharmaceutical industry, Immunocore, Physiology

NEWTOWN SQUARE, Pa., Feb. 15, 2022 (GLOBE NEWSWIRE) -- ArriVent Biopharma, Inc., industry leaders dedicated to accelerating the global development of innovative biopharmaceutical products, today announced the appointment ofBahija Jallal, Ph.D.to its Board of Directors.

Key Points: 
  • NEWTOWN SQUARE, Pa., Feb. 15, 2022 (GLOBE NEWSWIRE) -- ArriVent Biopharma, Inc., industry leaders dedicated to accelerating the global development of innovative biopharmaceutical products, today announced the appointment ofBahija Jallal, Ph.D.to its Board of Directors.
  • We are pleased to welcome an executive with Bahijas extensive senior leadership experience to our Board of Directors, saidBing Yao, Chairman, Co-founder and Chief Executive Officer of ArriVent.
  • Bahija is an internationally recognized biopharmaceutical leader, known for her entrepreneurial approach to discovering and delivering innovative biologics products to patients.
  • Through strategic collaborations with innovative biopharma companies, ArriVent aims to globalize medicines for patients with a broad range of diseases, with an initial focus in oncology.

Rewind Therapeutics appoints Anja Harmeier, PhD, MBA, as Chief Executive Officer

Retrieved on: 
수요일, 9월 22, 2021
Therapy, Max Planck Institute of Biochemistry, Patient, Berlin, Institute, Fund, Rewind, Neuroscience, Board, Biochemistry, Company, Roche, Degenerative disease, Entrada, Science, Pfizer, IE Business School, MBA, D, Investment, Doctor of Philosophy, Franchise, Multiple sclerosis, Director, Management, Fine chemical, Pharmaceutical industry

LEUVEN, Belgium, Sept. 22, 2021 /PRNewswire/ --Rewind Therapeutics ("Rewind"), a private Belgian biotech company developing innovative first-in-class remyelinating therapies for multiple sclerosis and other myelin-related diseases, announces the appointment of Anja Harmeier, PhD, MBA, as Chief Executive Officer.

Key Points: 
  • LEUVEN, Belgium, Sept. 22, 2021 /PRNewswire/ --Rewind Therapeutics ("Rewind"), a private Belgian biotech company developing innovative first-in-class remyelinating therapies for multiple sclerosis and other myelin-related diseases, announces the appointment of Anja Harmeier, PhD, MBA, as Chief Executive Officer.
  • She brings extensive R&D and operational capabilities complemented by a strong track record in company development and venture capital.
  • Jim Van heusden, Executive Chairman, commented "We are delighted to welcome Anja to the team.
  • Dr. Anja Harmeier added: "I am excited to be working with the team at Rewind.

Rewind Therapeutics appoints Anja Harmeier, PhD, MBA, as Chief Executive Officer

Retrieved on: 
수요일, 9월 22, 2021
Therapy, Max Planck Institute of Biochemistry, Patient, Berlin, Institute, Fund, Rewind, Neuroscience, Board, Biochemistry, Company, Roche, Degenerative disease, Entrada, Science, Pfizer, IE Business School, MBA, D, Investment, Doctor of Philosophy, Franchise, Multiple sclerosis, Director, Management, Fine chemical, Pharmaceutical industry

LEUVEN, Belgium, Sept. 22, 2021 /PRNewswire/ --Rewind Therapeutics ("Rewind"), a private Belgian biotech company developing innovative first-in-class remyelinating therapies for multiple sclerosis and other myelin-related diseases, announces the appointment of Anja Harmeier, PhD, MBA, as Chief Executive Officer.

Key Points: 
  • LEUVEN, Belgium, Sept. 22, 2021 /PRNewswire/ --Rewind Therapeutics ("Rewind"), a private Belgian biotech company developing innovative first-in-class remyelinating therapies for multiple sclerosis and other myelin-related diseases, announces the appointment of Anja Harmeier, PhD, MBA, as Chief Executive Officer.
  • She brings extensive R&D and operational capabilities complemented by a strong track record in company development and venture capital.
  • Jim Van heusden, Executive Chairman, commented "We are delighted to welcome Anja to the team.
  • Dr. Anja Harmeier added: "I am excited to be working with the team at Rewind.